Week of June 25, 2012: Bend Research, Catalent Enter into Oral Controlled-Release Technologies Pact; Quintiles Expands in China; and More
Bend Research, Catalent Enter into Oral Controlled-Release Technologies Pact; Quintiles Expands in China; and More.
Adventrx and Patheon have entered into a manufacturing agreement under which Patheon will formulate, fill, and finish ANX-188 drug product for use in clinical trials, including the Phase III study of ANX-188 that AdventRX plans to initiate this year. Read More
Bend Research and Catalent Pharma Solutions have agreed to provide services for pharmaceutical companies seeking to develop and manufacture specialized multiparticulate oral controlled-release products. Under the agreement, the companies will provide an integrated approach designed to bring complex controlled-release products to market faster and more efficiently with optimal therapeutic and release profiles. Read More
Merck Serono and Compugen, a therapeutic product-discovery company, has established Neviah Genomics, a start-up company focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity. Neviah Genomics will be operating out of the Merck Serono Israel Bioincubator. Merck Serono Ventures will provide the initial funding for Neviah Genomics. Compugen will use certain proprietary predictive discovery technologies and receive an equity ownership in the new company and a right to royalties from potential future sales. Read More
The CRO Quintiles has agreed to establish a regional headquarters in Shanghai, to significantly expand laboratory-testing capabilities in China. Under a joint venture agreement, Quintiles will engage Shanghai Clinical Research Center to provide laboratory-testing services to local customers. To provide the infrastructure essential for its growth strategy in China, Quintiles is investing $14 million to establish a new 4000-m2 (43,000 ft2) headquarters in Shanghai to serve China and nearby Asian countries. Read More
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
